ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that further to the announcement of 30 October 2017 and General Admission earlier today, the Fundraising and Acquisition of certain assets of Axela Inc. is now complete.
| GUILDFORD, ENGLAND -- (Marketwired) -- Nov 01, 2017 -- Angle PLC ( For immediate release 1 November 2017 ANGLE plc (“the Company”) Completion of Fundraising and Acquisition ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that further to the announcement of 30 October 2017 and General Admission earlier today, the Fundraising and Acquisition of certain assets of Axela Inc. is now complete. Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement entitled “Acquisition and Fundraising” released on 5 October 2017 unless the context requires otherwise. For further information ANGLE:
ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director finnCap Ltd (NOMAD and Joint Broker) +44 (0) 207 220 0500 Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain WG Partners (Joint Broker) +44 (0) 203 705 9330 Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000 Kimberly Ha (US) +1 212 850 5612 Notes for editors About ANGLE plc www.angleplc.com ANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis. ANGLE’s cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States. ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/ The analysis of the cells that can be harvested from patient blood with ANGLE’s Parsortix™ system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer. The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix™ system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness. As well as cancer, the Parsortix™ technology has the potential for deployment with several other important cell types in the future. ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com
Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com
|
